Skip to main content

Cosyntropin Depot FDA Approval Status

FDA Approved: No
Brand name: Cosyntropin Depot
Company: Assertio Therapeutics, Inc.
Treatment for: Adrenocortical Insufficiency

Cosyntropin Depot is an alcohol-free, long-acting formulation of a synthetic ACTH analogue in development for use as a diagnostic in the screening of patients presumed to have adrenocortical insufficiency.

Development timeline for Cosyntropin Depot

Oct 21, 2019Assertio Therapeutics Provides Regulatory Update on Long-Acting Cosyntropin
Dec 20, 2018Assertio Therapeutics Announces Submission of NDA for FDA Approval of Cosyntropin Depot

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.